Proviron 25 25mg/tab 60 Tabletten by Sterling Knight Pharmaceuticals

Usage

1. Identify the specific compound(s) used and look up their documented half-lives to calculate the ester clearance window before starting mesterolone.
2. For oral-only cycles, begin 25 mg mesterolone on the morning after your final oral dose; for injectable esters, wait five half-lives of the longest-acting compound before introduction.
3. Take the 25 mg tablet whole with water — the single-tablet dose requires no splitting and eliminates measurement error across any compound-specific protocol phase.
4. Stack mesterolone with an appropriate SERM (Clomiphene or Tamoxifen) from day one of PCT; the SERM drives gonadotropin output while mesterolone manages SHBG during the same window.
5. For Trenbolone or Nandrolone post-cycle periods, request a blood panel (LH, FSH, total testosterone, SHBG, prolactin) at weeks 4 and 8 to confirm recovery trajectory and determine whether extending beyond the initial protocol duration is warranted.
6. Do not discontinue mesterolone abruptly at the protocol end; if running 10–12 week courses for 19-nor cycles, step the final week down to alternate-day dosing before stopping to avoid abrupt SHBG rebound.

Warnings

Frequently asked questions

What PCT support does mesterolone provide after a Trenbolone cycle specifically?

After a Trenbolone cycle, mesterolone addresses SHBG elevation and androgen availability during recovery while the progestogenic suppression Trenbolone adds prolongs the overall axis restart. Because Trenbolone's half-life (approximately 2–3 days for acetate, 5–7 days for enanthate, per pharmacokinetic literature) means clearance is faster than testosterone enanthate, mesterolone can be introduced relatively early — but the PCT window itself should be extended to 10–12 weeks to account for deeper neuroendocrine suppression.

Is the PCT protocol genuinely different after a straight testosterone cycle compared to 19-nor compounds?

Yes, meaningfully so. After testosterone-only cycles, suppression is limited to the HPG axis without the added progestogenic burden that Trenbolone or Nandrolone introduce. Mesterolone at 25 mg daily for 6–8 weeks alongside a SERM is typically adequate. After 19-nor inclusion, most practitioners extend mesterolone use to 10–12 weeks and may incorporate an HCG phase first, because progestogenic receptor engagement at the pituitary level delays gonadotropin recovery independently of ester clearance.

What applies to PCT after an oral-only anabolic cycle when using mesterolone?

Oral-only cycles feature the shortest compound clearance window of any AAS category: agents like Methandienone clear within 24–48 hours based on their 8–16 hour half-lives. This means mesterolone can be started the day after the last oral dose. The recommended duration is shorter too — 4 to 6 weeks at 25 mg daily is frequently cited for shallow, oral-only suppression — making the 60-tablet Sterling Knight Proviron 25 pack ideal for covering one to two complete oral-only recovery courses.

Why is 25 mg per tablet relevant for compound-specific dosing flexibility?

At 25 mg per tablet, Sterling Knight Proviron 25 delivers the standard clinical mesterolone dose in a single unit, eliminating the need to split tablets — a practical advantage when protocols require precise daily amounts across different compound-specific phases. For Trenbolone or Nandrolone PCT running 12 weeks at 25 mg/day, the 60-tablet pack provides exactly the correct quantity without purchasing additional packs or managing excess inventory.

How does the 60-tablet pack size align with compound-specific PCT durations for Deca (Nandrolone Decanoate)?

Nandrolone Decanoate carries one of the longest ester half-lives in common use — approximately 14–16 days — meaning five half-lives of clearance extend to 70–80 days post-final injection before the recovery window opens. Once mesterolone is introduced, the PCT itself runs 10–12 weeks given Deca's deep HPG suppression. The 60-tablet Sterling Knight Proviron 25 pack covers a full 60-day daily-dose phase at 25 mg, typically representing the mesterolone portion of the first two-thirds of a Deca-specific recovery protocol. (2) angle_used

Manufacturer

Sterling Knight Pharmaceuticals' product development rationale for Proviron 25 is rooted in a specific observation: across its AAS catalogue, the compounds most frequently preceding PCT — testosterone esters, 19-nor progestins, and oral agents — impose fundamentally different suppression depths and clearance kinetics, which in turn require that the mesterolone product used in recovery can be relied upon for absolute per-tablet accuracy across every production run. To meet this requirement, each Proviron 25 batch is subjected to HPLC content-uniformity analysis using a certified mesterolone reference standard; the result is a per-lot instrument-derived potency figure that is traceable to a specific production record rather than inferred from formulation parameters. This traceability matters most at the compound-specific boundary conditions of PCT — the 12-week Deca recovery, the extended Trenbolone washout — where protocol integrity depends on knowing that tablet 60 delivers precisely what tablet 1 did.